Biome appoints incoming Chief Financial Officer
Released
Released
Announcement PDF
ASX ANNOUNCEMENT
4 December 2025
Biome appoints Lauren Dwyer as incoming Chief Financial Officer
● Chartered Accountant with 15 years' post-qualified experience across SaaS,
healthcare and complementary medicine sectors
● Experience leading finance functions in listed companies in Australia and
the United Kingdom (ASX, Smith & Nephew, Swisse Wellness and Amcor)
and for PE-backed high-growth businesses (Juno Pharmaceuticals and
vintrace)
● Proven track record executing international expansion, systems
transformation and M&A integration
● Outgoing CFO Douglas Loh to retire following comprehensive handover,
retaining advisory role
Microbiome health company Biome Australia Limited (ASX: BIO) ('Biome' or 'the
Company') is pleased to announce the appointment of Lauren Dwyer as incoming
Chief Financial Officer, effective 2 February 2026.
Ms Dwyer is a Chartered Accountant with a Big Four foundation (KPMG) and
brings 15 years of post-qualified experience across SaaS, healthcare,
pharmaceutical and complementary medicine sectors. She joins Biome from
vintrace, a private equity-backed SaaS business providing cloud technology
solutions to wineries globally, where she served as Director of Finance.
At vintrace, Ms Dwyer was tasked with establishing the finance function from
scratch following a US private equity acquisition, successfully leading multiple
concurrent software migrations including transitions to NetSuite and Rippling
while supporting the integration with US-based Encompass Technologies. Ms
Dwyer’s experience driving subscription pricing optimisation and Annual
Recurring Revenue growth is directly relevant to Biome's international expansion
and Vision 27 objectives.
Prior to vintrace, Ms Dwyer held the role of Chief Financial Officer at Juno
Pharmaceuticals, a generic pharmaceuticals business, where she was a member
of the Executive Leadership Team with responsibility for board reporting, investor
relations, M&A activity and operational leadership of five direct reports across
management accounting, accounts payable and accounts receivable functions.
Ms Dwyer's earlier career includes senior finance leadership roles at Swisse
Wellness (HKSE-listed), where she managed the Australian finance function
during global expansion across five international markets, and Lotte Duty Free,
where she project-managed the successful sale of JR Duty Free to the Lotte Group,
including development of the Transitional Services Agreement and post-
acquisition integration activities. She has also held statutory reporting roles at the
Australian Securities Exchange (ASX), Smith & Nephew (FTSE100) and Amcor
(ASX100), bringing deep experience in public company reporting, compliance and
investor communications.
Ms Dwyer holds a Bachelor of Commerce (Major in Accounting) from Queensland
University of Technology and is a member of the Australian Institute of Company
Directors.
CFO Transition
The Board initiated a Chief Financial Officer succession process approximately six
months ago as part of its ongoing executive planning. Following a comprehensive
search, the Board is pleased to appoint Ms Dwyer, an experienced and highly
qualified finance executive.
Mr Loh will retire in 2026 following a structured handover period and will continue
to support the Company in a limited advisory capacity to ensure a smooth
transition. The Board extends its sincere gratitude to Mr Loh for his significant
contribution to Biome’s growth, including seven consecutive quarters of positive
EBITDA and the Company’s first full year of net profit.
Biome Australia Managing Director and Founder Blair Norfolk said:
"Lauren brings exactly the sophistication and scale capability we need as Biome
executes on our international expansion strategy. Lauren’s experience building
finance functions for PE-backed SaaS businesses, combined with her track record
in listed company reporting and M&A integration, positions her perfectly to
support our next phase of growth.
Her experience at Swisse Wellness during their global expansion is particularly
relevant as we scale our operations across Canada, Ireland, New Zealand and the
US. Lauren's background in healthcare and complementary medicine means she
understands our sector intimately.
I would also like to thank Douglas for his significant contribution to Biome over
his tenure. Douglas has been instrumental in building the financial foundations
that have enabled us to achieve profitability, and I'm pleased he will remain
connected to the Company in an advisory capacity."
–ENDS–
This announcement has been authorised for release by the Board of Biome Australia
Limited.
About Biome Australia Limited
Biome Australia develops, licenses, commercializes and markets innovative, evidence-
based live biotherapeutics (probiotics) and complementary medicines supported by
clinical research. Biome aims to improve health outcomes and quality of life, making
products accessible through professional health channels.
Incorporated in Australia in 2018, Biome distributes locally and internationally. In
partnership with leading microbiome research organizations, Biome produces unique
live biotherapeutic products with innovative delivery technologies improving stability and
efficacy for its flagship Activated Probiotics® range.
Supported by randomized double-blind placebo-controlled clinical trials, Activated
Probiotics® and Activated Therapeutics® help prevent and support management of
various health concerns including low mood and sleep, bone health, iron malabsorption,
mild eczema and IBS. Through practitioner-recommended distribution, Biome educates
health professionals on gut microbiota's systemic health effects, providing evidence-
based natural medicines for prevalent chronic health concerns.
For more information visit: www.biomeaustralia.com
Investor Relations
Rechelle Friend
corporate@biomeaustralia.com
Media enquiries
media@activated.co
Forward Looking Statements
This release contains forward looking statements, including projections, guidance on
future revenues, earnings and estimates regarding Biome's future performance
(Forward Looking Statements). Forward Looking Statements are provided as general
guidance only and should not be relied upon as indication or guarantee of future
performance. Actual results, performance or achievements may differ materially from
those expressed or implied in Forward Looking Statements. Such statements assume
success of Biome's business strategies. You are cautioned not to place undue reliance on
Forward Looking Statements.
Forward Looking Statements are based on information available to Biome as at the
date of this release. Nothing in this release is a promise or representation as to the
future. No representation or warranty, express or implied, is made as to accuracy,
likelihood of achievement or reasonableness of Forward Looking Statements contained
in this release. Except as required by law or regulation (including ASX Listing Rules),
Biome does not undertake to provide additional or updated information whether as
result of changed expectations, new information, future events or otherwise.
To the maximum extent permitted by law, Biome excludes and expressly disclaims all
liabilities in respect of, and makes no representation or warranty, express or implied as
to fairness, currency, accuracy, reliability or completeness of information in this release
or accuracy, likelihood of achievement or reasonableness of Forward Looking
Statements contained in, implied by, or part of this release, or that this release contains
all material information about Biome which prospective investors may require in
evaluating possible investment in Biome.
Share your feedback
Discover